Progression of cardiac allograft vascular disease as assessed by serial intravascular ultrasound: correlation to immunological and non-immunological risk factors

被引:19
作者
Pethig, K [1 ]
Klauss, V
Heublein, B
Mudra, H
Westphal, A
Weber, C
Theisen, K
Haverich, A
机构
[1] Hannover Med Sch, Div Surg, Dept Thorac & Cardiovasc Surg, D-30623 Hannover, Germany
[2] Univ Munich, Dept Internal Med, Div Cardiol, Klinikum Innenstadt, Munich, Germany
关键词
heart transplantation; cardiac allograft vasculopathy; intravascular ultrasound;
D O I
10.1136/heart.84.5.494
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-To characterise the severity and progression of cardiac allograft vascular disease (CAVD) in a large patient cohort, and to evaluate possible immunological and nonimmunological risk factors for progression. Design-A prospective observational study using intravascular ultrasound. Setting-Two university hospitals. Patients and main outcome measures-Changes in focal plaque, lumen, and total vessel area (worst site method) were assessed at baseline and after 12.1 (2.8) months (mean (SD)) of follow up in a cohort of 96 patients (79 male, 17 female; mean age 48.7 (9.6) years; time post-transplant 26.0 (32.4) months). Results-Overall, the mean (SD) intimal index of worst sites increased by 6.7 (8.8)%. The increase in the first 12 months was 7.5 (9.4)%, v 5.9 (8.0)% after the first year (NS). Analysing immunological and non-immunological risk factors (age, underlying disease, sex, donor age, immunosuppression, cytomegalovirus, rejection episodes, cholesterol), low density lipoprotein (LDL) cholesterol was found to be the most important predictor of severe progression las defined by an increase in intimal index of greater than or equal to 15% (p = 0.01). Conclusions-Progression of CAVD is characterised by a continuing increase in intimal hyperplasia, especially within the first year after heart transplantation. LDL cholesterol is an important predictor of major progression.
引用
收藏
页码:494 / 498
页数:5
相关论文
共 38 条
[1]   FUNCTIONAL-SIGNIFICANCE OF INTIMAL THICKENING AS DETECTED BY INTRAVASCULAR ULTRASOUND EARLY AND LATE AFTER CARDIAC TRANSPLANTATION [J].
ANDERSON, TJ ;
MEREDITH, IT ;
UEHATA, A ;
MUDGE, GH ;
SELWYN, AP ;
GANZ, P ;
YEUNG, AC .
CIRCULATION, 1993, 88 (03) :1093-1100
[2]  
Chenzbraun A, 1995, J Am Soc Echocardiogr, V8, P1, DOI 10.1016/S0894-7317(05)80351-7
[3]  
COSTANZONORDIN MR, 1992, J HEART LUNG TRANSPL, V11, P90
[4]   CARDIAC ALLOGRAFT VASCULOPATHY ASSESSED BY INTRAVASCULAR ULTRASONOGRAPHY AND NONIMMUNOLOGICAL RISK-FACTORS [J].
ESCOBAR, A ;
VENTURA, HO ;
STAPLETON, DD ;
MEHRA, MR ;
RAMEE, SR ;
COLLINS, TJ ;
JAIN, SP ;
SMART, FW ;
WHITE, CJ .
AMERICAN JOURNAL OF CARDIOLOGY, 1994, 74 (10) :1042-1046
[5]   ACCELERATED CORONARY VASCULAR-DISEASE IN THE HEART-TRANSPLANT PATIENT - CORONARY ARTERIOGRAPHIC FINDINGS [J].
GAO, SZ ;
ALDERMAN, EL ;
SCHROEDER, JS ;
SILVERMAN, JF ;
HUNT, SA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1988, 12 (02) :334-340
[6]  
Gibbons GH, 1995, J HEART LUNG TRANSPL, V14, pS149
[7]   Coronary artery stenting in cardiac allograft vascular disease [J].
Heublein, B ;
Pethig, K ;
Maass, C ;
Wahlers, T ;
Haverich, A .
AMERICAN HEART JOURNAL, 1997, 134 (05) :930-938
[8]  
Hornick P, 1997, CIRCULATION, V96, P148
[9]  
HOSENPUD JD, 1992, J HEART LUNG TRANSPL, V11, P9
[10]  
JOHNSON DE, 1989, J HEART TRANSPLANT, V8, P349